Similar articles

• [Atrial fibrillation: new anticoagulants are more effective and safer, but expensive].

  Steurer J. Steurer J. Praxis (Bern 1994). 2014 Jun 18;103(13):785-6. doi: 10.1024/1661-8157/a001681. Praxis (Bern 1994). 2014. PMID: 24938162 Review. German. No abstract available.
• Making decisions about antithrombotic therapy in heart disease: decision analytic and cost-effectiveness issues.

  Eckman MH, Levine HJ, Salem DN, Pauker SG. Eckman MH, et al. Chest. 1998 Nov;114(5 Suppl):699S-714S. doi: 10.1378/chest.114.5_supplement.699s. Chest. 1998. PMID: 9822072 No abstract available.
• Quality of anticoagulation control in atrial fibrillation.

  Lane DA, Lip GY. Lane DA, et al. Lancet. 2010 Sep 18;376(9745):935-7. doi: 10.1016/S0140-6736(10)61305-0. Lancet. 2010. PMID: 20801499 No abstract available.
• Incidence of thromboembolic complications in patients with atrial fibrillation or mechanical heart valves with a subtherapeutic international normalized ratio: a prospective multicenter cohort study.

  Dentali F, Pignatelli P, Malato A, Poli D, Di Minno MN, Di Gennaro L, Rancan E, Pastori D, Grifoni E, Squizzato A, Siragusa S, Di Minno G, Ageno W. Dentali F, et al. Am J Hematol. 2012 Apr;87(4):384-7. doi: 10.1002/ajh.23119. Epub 2012 Feb 24. Am J Hematol. 2012. PMID: 22367852
• Risk of ischemic stroke and hemorrhagic complications in warfarinized patients with non-valvular atrial fibrillation.

  Uchiyama S. Uchiyama S. Intern Med. 2001 Dec;40(12):1166-7. doi: 10.2169/internalmedicine.40.1166. Intern Med. 2001. PMID: 11813834 Review. No abstract available.